Product Pipeline
Corixa has characterized numerous antigens discovered under our lung cancer collaborations with Japan Tobacco and Zambon Group spa. We have identified a candidate antigen and the FDA has allowed us to proceed with a Phase I clinical trial for a non-small cell lung carcinoma vaccine candidate that we expect to initiate in 2003.

Related News
02/04/2003 Corixa provides update on lung cancer vaccine program
07/31/2001 Corixa receives $1 million milestone payment from Japan Tobacco
06/16/1999 Corixa partners with Japan Tobacco
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.